The sympathetic nervous system and the metabolic syndrome.
暂无分享,去创建一个
G. Mancia | J. Elghozi | G. Grassi | S. Julius | J. Reid | M. Esler | P. Bousquet | P. V. van Zwieten
[1] I. Wittmann. Insulin Resistance and Metabolic Syndrome , 2007, EJIFCC.
[2] G. Mancia,et al. Metabolic Syndrome in the Pressioni Arteriose Monitorate E Loro Associazioni (PAMELA) Study: Daily Life Blood Pressure, Cardiac Damage, and Prognosis , 2007, Hypertension.
[3] Elisabeth Lambert,et al. Mechanisms of sympathetic activation in obesity-related hypertension. , 2006, Hypertension.
[4] Francesco Locatelli,et al. Renal manifestations in the metabolic syndrome. , 2006, Journal of the American Society of Nephrology : JASN.
[5] S. Haffner,et al. Geographic variations of the International Diabetes Federation and the National Cholesterol Education Program-Adult Treatment Panel III definitions of the metabolic syndrome in nondiabetic subjects. , 2006, Diabetes care.
[6] M. Muggeo,et al. Clinical efficacy and tolerability of alpha-blocker doxazosin as add-on therapy in patients with hypertension and impaired glucose metabolism. , 2006, Nutrition, metabolism, and cardiovascular diseases : NMCD.
[7] Ian Janssen,et al. The importance of waist circumference in the definition of metabolic syndrome: prospective analyses of mortality in men. , 2006, Diabetes care.
[8] Y. Nakaya,et al. Relationships between thermic effect of food, insulin resistance and autonomic nervous activity. , 2006, The journal of medical investigation : JMI.
[9] A. Karter,et al. Prediction of Type 2 Diabetes Mellitus With Alternative Definitions of the Metabolic Syndrome: The Insulin Resistance Atherosclerosis Study , 2005, Circulation.
[10] R. D'Agostino,et al. Metabolic Syndrome as a Precursor of Cardiovascular Disease and Type 2 Diabetes Mellitus , 2005, Circulation.
[11] P. Nestel,et al. Effects of dietary weight loss on sympathetic activity and cardiac risk factors associated with the metabolic syndrome. , 2005, The Journal of clinical endocrinology and metabolism.
[12] R. Krauss,et al. Diagnosis and Management of the Metabolic Syndrome: An American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement , 2005, Current opinion in cardiology.
[13] Yuichiro Oka,et al. Metabolic syndrome and carotid atherosclerosis: role of elevated blood pressure. , 2005, Journal of atherosclerosis and thrombosis.
[14] Fernando Costa,et al. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. , 2005, Circulation.
[15] Kathryn Bean,et al. Cardiovascular Mortality in Overweight Subjects: The Key Role of Associated Risk Factors , 2005, Hypertension.
[16] Paul Zimmet,et al. The metabolic syndrome—a new worldwide definition , 2005, The Lancet.
[17] J. Oppert,et al. Metabolic syndrome in relation to structure and function of large arteries: a predominant effect of blood pressure. A report from the SU.VI.MAX. Vascular Study. , 2005, American journal of hypertension.
[18] G. Mancia,et al. Obstructive Sleep Apnea–Dependent and –Independent Adrenergic Activation in Obesity , 2005, Hypertension.
[19] K. Mather,et al. Obesity, Insulin Resistance, and the Metabolic Syndrome: Determinants of Endothelial Dysfunction in Whites and Blacks , 2005, Circulation.
[20] G. Mancia,et al. Neuroadrenergic and reflex abnormalities in patients with metabolic syndrome , 2005, Diabetologia.
[21] S. Srinivasan,et al. Influence of metabolic syndrome on arterial stiffness and its age-related change in young adults: the Bogalusa Heart Study. , 2005, Atherosclerosis.
[22] M. Tarnopolsky,et al. Regulating adiponectin: of flax and flux , 2005, Diabetologia.
[23] K. Petersen,et al. Mechanisms of insulin resistance in humans and possible links with inflammation. , 2005, Hypertension.
[24] G. Leoncini,et al. Metabolic syndrome is associated with early signs of organ damage in nondiabetic, hypertensive patients , 2005, Journal of internal medicine.
[25] F. Magrini,et al. Prevalence and correlates of left atrial enlargement in essential hypertension: role of ventricular geometry and the metabolic syndrome: The Evaluation of Target Organ Damage in Hypertension study , 2005, Journal of hypertension.
[26] N. Shostak,et al. Comparison of rilmenidine and lisinopril on ambulatory blood pressure and plasma lipid and glucose levels in hypertensive women with metabolic syndrome , 2005, Current medical research and opinion.
[27] N. Wong,et al. Cardiovascular disease in U.S. patients with metabolic syndrome, diabetes, and elevated C-reactive protein. , 2005, Diabetes care.
[28] R. Bergman,et al. Molecular evidence supporting the portal theory: a causative link between visceral adiposity and hepatic insulin resistance. , 2005, American journal of physiology. Endocrinology and metabolism.
[29] A. F. Mackintosh,et al. Sympathetic Neural Activation in Nondiabetic Metabolic Syndrome and Its Further Augmentation by Hypertension , 2004, Hypertension.
[30] G. Mancia,et al. Effect of central and peripheral body fat distribution on sympathetic and baroreflex function in obese normotensives , 2004, Journal of hypertension.
[31] G. Doronzo,et al. Insulin activates vascular endothelial growth factor in vascular smooth muscle cells: influence of nitric oxide and of insulin resistance , 2004, European journal of clinical investigation.
[32] F. Magrini,et al. Metabolic syndrome and target organ damage in untreated essential hypertensives , 2004, Journal of hypertension.
[33] Nathan D. Wong,et al. Impact of the Metabolic Syndrome on Mortality From Coronary Heart Disease, Cardiovascular Disease, and All Causes in United States Adults , 2004, Circulation.
[34] G. Grassi. Counteracting the sympathetic nervous system in essential hypertension , 2004, Current opinion in nephrology and hypertension.
[35] Hong Tang,et al. Insulin resistance and endothelial dysfunction in type 2 diabetes patients with or without microalbuminuria. , 2004, Diabetes research and clinical practice.
[36] T. Ogihara,et al. Hypoadiponectinemia Is an Independent Risk Factor for Hypertension , 2004, Hypertension.
[37] G. Grassi. Leptin, sympathetic nervous system, and baroreflex function , 2004, Current hypertension reports.
[38] P. Calverley,et al. Obstructive sleep apnoea is independently associated with an increased prevalence of metabolic syndrome. , 2004, European heart journal.
[39] Ralph B D'Agostino,et al. Risk of complications of pregnancy in women with type 1 diabetes: nationwide prospective study in the Netherlands , 2004, BMJ : British Medical Journal.
[40] Sung Hee Choi,et al. Visceral fat thickness measured by ultrasonography can estimate not only visceral obesity but also risks of cardiovascular and metabolic diseases. , 2004, The American journal of clinical nutrition.
[41] Jing Chen,et al. The Metabolic Syndrome and Chronic Kidney Disease in U.S. Adults , 2004, Annals of Internal Medicine.
[42] E. Scott,et al. Impact of Type 2 Diabetes Mellitus on Sympathetic Neural Mechanisms in Hypertension , 2003, Circulation.
[43] Robert Wolk,et al. Obesity, Sleep Apnea, and Hypertension , 2003, Hypertension.
[44] E. Kraegen,et al. Insulin action, regional fat, and myocyte lipid: altered relationships with increased adiposity. , 2003, Obesity research.
[45] M. Carnethon,et al. Association between microalbuminuria and the metabolic syndrome: NHANES III. , 2003, American journal of hypertension.
[46] S. Haffner,et al. The metabolic syndrome as predictor of type 2 diabetes: the San Antonio heart study. , 2003, Diabetes care.
[47] G. Mancia,et al. Effects of Heart Rate Changes on Arterial Distensibility in Humans , 2003, Hypertension.
[48] G. Mancia,et al. European guidelines on cardiovascular disease prevention in clinical practice; Third Joint Task Force of European and other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of eight societies and by invited experts) , 2003, European journal of cardiovascular prevention and rehabilitation : official journal of the European Society of Cardiology, Working Groups on Epidemiology & Prevention and Cardiac Rehabilitation and Exercise Physiology.
[49] P. Macfarlane,et al. Metabolic Syndrome With and Without C-Reactive Protein as a Predictor of Coronary Heart Disease and Diabetes in the West of Scotland Coronary Prevention Study , 2003, Circulation.
[50] A. Zanchetti,et al. Is there a relationship between left ventricular mass and plasma glucose and lipids independent of body mass index? Results of the Gubbio Study. , 2003, Nutrition, metabolism, and cardiovascular diseases : NMCD.
[51] S. Priori,et al. 2003 European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension. , 2003, Journal of hypertension.
[52] Reubin Andres,et al. Metabolic syndrome amplifies the age-associated increases in vascular thickness and stiffness. , 2003, Journal of the American College of Cardiology.
[53] Arya M. Sharma,et al. Association between adiponectin and mediators of inflammation in obese women. , 2003, Diabetes.
[54] S. Lewington. Prospective studies collaboration. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies (vol 360, pg 1903, 2002) , 2003 .
[55] Shankuan Zhu,et al. The metabolic syndrome: prevalence and associated risk factor findings in the US population from the Third National Health and Nutrition Examination Survey, 1988-1994. , 2003, Archives of internal medicine.
[56] R. Collins,et al. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies , 2002, The Lancet.
[57] Jukka T Salonen,et al. The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. , 2002, JAMA.
[58] S. Uchida,et al. Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase , 2002, Nature Medicine.
[59] G. Mancia,et al. Short- and Long-Term Neuroadrenergic Effects of Moderate Dietary Sodium Restriction in Essential Hypertension , 2002, Circulation.
[60] G. Mancia,et al. Arterial distensibility in humans. Modulating mechanisms, alterations in diseases and effects of treatment. , 2002, Journal of hypertension.
[61] H. Snieder,et al. Insulin Resistance Syndrome and Left Ventricular Mass in Healthy Young People , 2002, The American journal of the medical sciences.
[62] H. Koyama,et al. Insulin resistance as an independent predictor of cardiovascular mortality in patients with end-stage renal disease. , 2002, Journal of the American Society of Nephrology : JASN.
[63] R. Bergman,et al. Extreme insulin resistance of the central adipose depot in vivo. , 2002, Diabetes.
[64] A. Mark,et al. Selective Resistance to Central Neural Administration of Leptin in Agouti Obese Mice , 2002, Hypertension.
[65] G. Mancia,et al. Participation of the Hypothalamus-Hypophysis Axis in the Sympathetic Activation of Human Obesity , 2001, Hypertension.
[66] Daniel Levy,et al. Assessment of frequency of progression to hypertension in non-hypertensive participants in the Framingham Heart Study: a cohort study , 2001, The Lancet.
[67] J. Reid. Update on rilmenidine: clinical benefits. , 2001, American journal of hypertension.
[68] G. Grassi. Renin-angiotensin-sympathetic crosstalks in hypertension: reappraising the relevance of peripheral interactions. , 2001, Journal of hypertension.
[69] Y. Terauchi,et al. The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity , 2001, Nature Medicine.
[70] S. Yusuf,et al. Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals. , 2001, JAMA.
[71] L. Landsberg. Insulin-mediated sympathetic stimulation: role in the pathogenesis of obesity-related hypertension (or, how insulin affects blood pressure, and why) , 2001, Journal of hypertension.
[72] T. Pischon,et al. Hypothesis: β-Adrenergic Receptor Blockers and Weight Gain , 2001 .
[73] R. Bergman,et al. Free Fatty Acids and Pathogenesis of Type 2 Diabetes Mellitus , 2000, Trends in Endocrinology & Metabolism.
[74] B. Trimarco,et al. Haemodynamic and metabolic effects of rilmenidine in hypertensive patients with metabolic syndrome X. A double‐blind parallel study versus amlodipine , 2000, Journal of hypertension.
[75] G. Mancia,et al. Adrenergic and Reflex Abnormalities in Obesity-Related Hypertension , 2000, Hypertension.
[76] S. O'Sullivan,et al. The effects of exercise and training on human cardiovascular reflex control. , 2000, Journal of the autonomic nervous system.
[77] S. Klaus,et al. Resting metabolic rate and substrate use in obesity hypertension. , 2000, Hypertension.
[78] T Nakamura,et al. Plasma concentrations of a novel, adipose-specific protein, adiponectin, in type 2 diabetic patients. , 2000, Arteriosclerosis, thrombosis, and vascular biology.
[79] M. Laakso,et al. Insulin resistance syndrome predicts the risk of coronary heart disease and stroke in healthy middle-aged men: the 22-year follow-up results of the Helsinki Policemen Study. , 2000, Arteriosclerosis, thrombosis, and vascular biology.
[80] G. Grassi,et al. Sympathetic activation in the pathogenesis of hypertension and progression of organ damage. , 1999, Hypertension.
[81] E. Feskens,et al. Glucose tolerance and mortality: comparison of WHO and American Diabetic Association diagnostic criteria , 1999, The Lancet.
[82] D. Seals,et al. Neural mechanisms in human obesity-related hypertension. , 1999, Journal of hypertension.
[83] N. Mikhail,et al. Obesity and hypertension. , 1999, Progress in cardiovascular diseases.
[84] G. Grassi,et al. How to assess sympathetic activity in humans. , 1999, Journal of hypertension.
[85] V. Somers,et al. Human obesity is characterized by a selective potentiation of central chemoreflex sensitivity. , 1999, Hypertension.
[86] A. Dyer,et al. Resting heart rate is a risk factor for cardiovascular and noncardiovascular mortality: the Chicago Heart Association Detection Project in Industry. , 1999, American journal of epidemiology.
[87] G Mancia,et al. Heart rate as marker of sympathetic activity , 1998, Journal of hypertension.
[88] V. Somers,et al. Sympathetic activity in obese subjects with and without obstructive sleep apnea. , 1998, Circulation.
[89] G. Mancia,et al. Body weight reduction, sympathetic nerve traffic, and arterial baroreflex in obese normotensive humans. , 1998, Circulation.
[90] C. Sartori,et al. Insulin as a vascular and sympathoexcitatory hormone: implications for blood pressure regulation, insulin sensitivity, and cardiovascular morbidity. , 1997, Circulation.
[91] G. Jennings,et al. Regional sympathetic nervous activity and oxygen consumption in obese normotensive human subjects. , 1997, Circulation.
[92] M. Böhm,et al. The Cardiac β-Adrenoceptor–Mediated Signaling Pathway and Its Alterations in Hypertensive Heart Disease , 1997 .
[93] G. Dagenais,et al. Small, dense low-density lipoprotein particles as a predictor of the risk of ischemic heart disease in men. Prospective results from the Québec Cardiovascular Study. , 1997, Circulation.
[94] K. Petersen,et al. Mechanism of free fatty acid-induced insulin resistance in humans. , 1996, The Journal of clinical investigation.
[95] B. Duncan,et al. A Metabolic Syndrome in Whites and African-Americans: The Atherosclerosis Risk in Communities baseline study , 1996, Diabetes Care.
[96] G. Reaven,et al. Hypertension and associated metabolic abnormalities--the role of insulin resistance and the sympathoadrenal system. , 1996, The New England journal of medicine.
[97] G. Mancia,et al. Sympathetic modulation of radial artery compliance in congestive heart failure. , 1995, Hypertension.
[98] G. Mancia,et al. Sympathetic activation in obese normotensive subjects. , 1995, Hypertension.
[99] F. Sannajust,et al. Involvement of imidazoline-preferring receptors in regulation of sympathetic tone. , 1994, The American journal of cardiology.
[100] S. Julius,et al. Sympathetics, insulin resistance and coronary risk in hypertension: the 'chicken-and-egg' question. , 1994, Journal of hypertension.
[101] G. Mancia,et al. Physical training and baroreceptor control of sympathetic nerve activity in humans. , 1994, Hypertension.
[102] E. Ravussin,et al. Reduced sympathetic nervous activity. A potential mechanism predisposing to body weight gain. , 1993, The Journal of clinical investigation.
[103] P. Vollenweider,et al. Suppression of Insulin‐Induced Sympathetic Activation and Vasodilation by Dexamethasone in Humans , 1993, Circulation.
[104] L. Mandarino,et al. Interaction between glucose and free fatty acid metabolism in human skeletal muscle. , 1993, The Journal of clinical investigation.
[105] B. Trimarco,et al. Insulin reduces reflex forearm sympathetic vasoconstriction in healthy humans. , 1993, Hypertension.
[106] S. Julius,et al. Reflex sympathetic activation induces acute insulin resistance in the human forearm. , 1993, Hypertension.
[107] J. Neaton,et al. Diabetes, Other Risk Factors, and 12-Yr Cardiovascular Mortality for Men Screened in the Multiple Risk Factor Intervention Trial , 1993, Diabetes Care.
[108] A. Rantala,et al. Multiple metabolic syndrome: aspects of genetic epidemiology and molecular genetics. , 1992, Annals of medicine.
[109] L. Landsberg. Obesity and hypertension: experimental data. , 1992, Journal of hypertension. Supplement : official journal of the International Society of Hypertension.
[110] J. K. Dunn,et al. Relation of triglyceride metabolism and coronary artery disease. Studies in the postprandial state. , 1992, Arteriosclerosis and thrombosis : a journal of vascular biology.
[111] A. Mark,et al. Insulin Increases Sympathetic Activity but Not Blood Pressure in Borderline Hypertensive Humans , 1992, Hypertension.
[112] Egan Bm. Neurohumoral, hemodynamic and microvascular changes as mechanisms of insulin resistance in hypertension: a provocative but partial picture. , 1991 .
[113] G. Jennings,et al. Biochemical evidence of sympathetic hyperactivity in human hypertension. , 1991, Hypertension.
[114] N. Schork,et al. Hyperkinetic borderline hypertension in Tecumseh, Michigan , 1991, Journal of hypertension.
[115] M. Laakso,et al. Decreased effect of insulin to stimulate skeletal muscle blood flow in obese man. A novel mechanism for insulin resistance. , 1990, The Journal of clinical investigation.
[116] E A Anderson,et al. Elevated Sympathetic Nerve Activity in Borderline Hypertensive Humans Evidence From Direct Intraneural Recordings , 1989, Hypertension.
[117] N. Kaplan. The Deadly Quartet: Upper-Body Obesity, Glucose Intolerance, Hypertriglyceridemia, and Hypertension , 1989 .
[118] G. Reaven. Banting lecture 1988. Role of insulin resistance in human disease. , 1988, Diabetes.
[119] G. Reaven. Role of Insulin Resistance in Human Disease , 1988, Diabetes.
[120] L. Landsberg,et al. Insulin and hypertension: lessons from obesity. , 1987, The New England journal of medicine.
[121] Y. Yamori,et al. Humoral trophic influence on cardiovascular structural changes in hypertension. , 1984, Hypertension.
[122] S. Schanberg,et al. Hypertension and cardiovascular hypertrophy during chronic catecholamine infusion in rats. , 1983, Life sciences.
[123] E. Rasio. Passage of glucose through the cell membrane of capillary endothelium. , 1975, American Journal of Physiology.
[124] M. Wellner,et al. Adipose tissue and circulating endothelial cell specific molecule-1 in human obesity. , 2006, Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme.
[125] G. Mancia,et al. New-onset diabetes and antihypertensive drugs. , 2006, Journal of Hypertension.
[126] J. Oppert,et al. Metabolic Syndrome in Relation to Structure and Function of Large Arteries: A Predominant Effect of Blood Pressure , 2005 .
[127] H. Hashimoto,et al. Hypertension Is the Most Common Component of Metabolic Syndrome and the Greatest Contributor to Carotid Arteriosclerosis in Apparently Healthy Japanese Individuals , 2005, Hypertension Research.
[128] B. Howard,et al. Comparison of cardiac structure and function in American Indians with and without the metabolic syndrome (the Strong Heart Study). , 2004, The American journal of cardiology.
[129] G. Mancia,et al. European guidelines on cardiovascular disease prevention in clinical practice. Third Joint Task Force of European and Other Societies on Cardiovascular Disease Prevention in Clinical Practice. , 2003, European heart journal.
[130] M. Stolar,et al. Type 2 diabetes, cardiovascular risk, and the link to insulin resistance. , 2003, Clinical therapeutics.
[131] A. Zanchetti,et al. European Society of Hypertension – European Society of Cardiology guidelines for the management of arterial hypertension , 2003 .
[132] Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. , 2002, Circulation.
[133] T. Pischon,et al. Hypothesis: Beta-adrenergic receptor blockers and weight gain: A systematic analysis. , 2001, Hypertension.
[134] A. Dyer,et al. Resting heart rate is a risk factor for cardiovascular and noncardiovascular mortality. , 1999 .
[135] S. Nesbitt,et al. Tachycardia: an important determinant of coronary risk in hypertension. , 1998, Journal of hypertension. Supplement : official journal of the International Society of Hypertension.
[136] G Mancia,et al. Baroreflex control of sympathetic nerve activity in essential and secondary hypertension. , 1998, Hypertension.
[137] T. Ogihara,et al. Sympathetic nerve hyperactivity precedes hyperinsulinemia and blood pressure elevation in a young, nonobese Japanese population. , 1997, American journal of hypertension.
[138] M. Castellano,et al. The cardiac beta-adrenoceptor-mediated signaling pathway and its alterations in hypertensive heart disease. , 1997, Hypertension.
[139] B. Wallin,et al. Increased norepinephrine spillover into the jugular veins in essential hypertension. , 1992, Hypertension.
[140] B. Egan. Neurohumoral, hemodynamic and microvascular changes as mechanisms of insulin resistance in hypertension: a provocative but partial picture. , 1991, International journal of obesity.
[141] G. Jennings,et al. Regional norepinephrine turnover in human hypertension. , 1989, Clinical and experimental hypertension. Part A, Theory and practice.
[142] N. Kaplan. The deadly quartet. Upper-body obesity, glucose intolerance, hypertriglyceridemia, and hypertension. , 1989, Archives of internal medicine.
[143] I. G. Joshua,et al. Distributions of microvascular pressure in skeletal muscle of one-kidney, one clip, two-kidney, one clip, and deoxycorticosterone-salt hypertensive rats. , 1984, Hypertension.